-

Bristol Myers Squibb to Participate in Barclays Virtual Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Barclays’ Virtual Global Healthcare Conference, which will be webcast on Tuesday, March 9, 2021. David Elkins, Executive Vice President, Chief Financial Officer will answer questions about the company at 3 p.m. ET.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Material related to the company’s presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

CorporateFinancial-News

Contacts

Bristol Myers Squibb
Media:
media@bms.com

Investor Relations:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, nina.goworek@bms.com

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb to Participate in Barclays Virtual Global Healthcare Conference
Release Versions

Contacts

Bristol Myers Squibb
Media:
media@bms.com

Investor Relations:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, nina.goworek@bms.com

More News From Bristol Myers Squibb

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma...

Bristol Myers Squibb Announces Dividend Increase

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend Increase...

Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025...
Back to Newsroom